title: The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance.
abstract: BACKGROUND
  Pathogens that establish chronic infection elicit immune responses with suppressive cytokines dominating over pro-inflammatory cytokines. Chronic hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection and simian immunodeficiency virus (SIV) infection are associated with high levels of antiviral antibodies expressing a common idiotype specifically recognized by the 1F7 monoclonal antibody (mAb). The 1F7 mAb is a murine IgMκ antibody raised against immunoglobulin pooled from the plasma of multiple HIV-infected individuals. In this study, we investigated direct effects of the 1F7 mAb itself on peripheral blood mononuclear cells (PBMC).
  
  
  METHODS
  Isolated monocytes or PBMC from healthy controls were incubated with the 1F7 mAb or IgMκ mAb control. Cytokine production was measured in cell culture supernatants by ELISA and cells producing interleukin-10 (IL-10) were identified by subset depletion and intracellular flow cytometry. Endotoxin tolerance was assessed by exposing monocytes to lipopolysaccharide (LPS) following 1F7 mAb or IgMκ mAb control pre-treatment and comparing tumor necrosis factor (TNF)-α levels in cell culture supernatants.
  
  
  RESULTS
  The 1F7 mAb stimulated monocytes and CD36+ lymphocytes to produce IL-10 in a time and dose-dependent manner. Treatment of monocytes with 1F7 mAb also reduced their subsequent responsiveness to LPS stimulation.
  
  
  CONCLUSIONS
  Induction of antibodies expressing the 1F7 idiotype by chronic pathogens may facilitate IL-10 production and progression to chronic infection. Direct effects of IL-10 from human monocytes stimulated by 1F7-like antibodies, followed by monocyte transition to an alternatively activated phenotype illustrated by endotoxin tolerance, are two complementary features favouring a tolerogenic or non-responsive immunological environment.
authors.affiliation: Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St, John's, NL, Canada. mgrant@mun.ca.
authors.forename: Tigran K
authors.initials: TK
authors.lastname: Davtyan
authors.forename: David A
authors.initials: DA
authors.lastname: Poghosyan
authors.forename: Anna G
authors.initials: AG
authors.lastname: Sukiasyan
authors.forename: Michael D
authors.initials: MD
authors.lastname: Grant
references.citation: J Med Virol. 2002 Jan;66(1):13-21
references.pmid: 11748653
references.citation: Inflamm Res. 2008 Feb;57(2):65-74
references.pmid: 18288456
references.citation: BMC Immunol. 2008 Jun 13;9:28
references.pmid: 18554409
references.citation: Gastroenterology. 2002 Oct;123(4):1070-83
references.pmid: 12360469
references.citation: J Leukoc Biol. 2011 Jun;89(6):981-8
references.pmid: 21385948
references.citation: Rev Med Virol. 2005 Jul-Aug;15(4):235-68
references.pmid: 15782389
references.citation: Annu Rev Immunol. 2001;19:683-765
references.pmid: 11244051
references.citation: Adv Exp Med Biol. 2012;750:198-212
references.pmid: 22903676
references.citation: J Immunol. 1991 Aug 1;147(3):933-41
references.pmid: 1861082
references.citation: Clin Liver Dis. 1997 Nov;1(3):515-28, v
references.pmid: 15560055
references.citation: Hepatology. 2007 Mar;45(3):623-30
references.pmid: 17326156
references.citation: Hepatology. 2004 Jun;39(6):1721-31
references.pmid: 15185314
references.citation: Scand J Immunol. 1993 Oct;38(4):327-34
references.pmid: 7692591
references.citation: Immunol Res. 2010 Jul;47(1-3):185-206
references.pmid: 20087682
references.citation: Eur J Immunol. 1992 Jul;22(7):1749-55
references.pmid: 1378015
references.citation: J Infect Dis. 2011 Apr 15;203(8):1087-95
references.pmid: 21398397
references.citation: J Viral Hepat. 1999 Jul;6 Suppl 1:31-5
references.pmid: 10760032
references.citation: J Gastroenterol Hepatol. 2012 Apr;27(4):823-31
references.pmid: 21871023
references.citation: Immunol Cell Biol. 1996 Feb;74(1):38-44
references.pmid: 8934652
references.citation: J Leukoc Biol. 2007 Mar;81(3):825-34
references.pmid: 17148690
references.citation: Pathobiology. 2006;73(1):26-39
references.pmid: 16785765
references.citation: Ann Immunol (Paris). 1984 Jan-Feb;135C(1):107-15
references.pmid: 6712157
references.citation: Hum Immunol. 2011 Oct;72(10):935-9
references.pmid: 21756957
references.citation: J Autoimmun. 2007 Dec;29(4):213-8
references.pmid: 17888629
references.citation: Immunol Cell Biol. 2009 Aug-Sep;87(6):457-63
references.pmid: 19333248
references.citation: Nat Med. 2006 Nov;12(11):1301-9
references.pmid: 17041596
references.citation: Biomed Pharmacother. 2004 Jun;58(5):276-81
references.pmid: 15194162
references.citation: J Clin Invest. 1995 Aug;96(2):775-80
references.pmid: 7635971
references.citation: J Autoimmun. 2007 Dec;29(4):246-9
references.pmid: 17888625
references.citation: Int Immunol. 1998 Jun;10(6):711-7
references.pmid: 9678751
references.citation: Hepatology. 1997 Feb;25(2):449-58
references.pmid: 9021963
references.citation: J Leukoc Biol. 2007 Jul;82(1):152-60
references.pmid: 17412916
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8
references.pmid: 12441397
references.citation: Scand J Clin Lab Invest. 1997 Dec;57(8):703-10
references.pmid: 9458493
references.citation: Arthritis Rheum. 1987 Jan;30(1):50-6
references.pmid: 3814197
references.citation: Clin Exp Immunol. 1997 Apr;108(1):138-43
references.pmid: 9097922
references.citation: Nat Clin Pract Rheumatol. 2008 Sep;4(9):491-8
references.pmid: 18756274
references.citation: Viral Immunol. 2010 Aug;23(4):359-68
references.pmid: 20712480
references.citation: Immunol Today. 1992 Dec;13(12):490-4
references.pmid: 1463581
references.citation: Clin Exp Immunol. 2005 Dec;142(3):481-9
references.pmid: 16297160